Click the puzzle for a full-size version. Note: The answer grid will include every letter of the alphabet.EMILY COX AND HENRY RATHVON

We’ve been working on it for a long time so to have it read out positively, it’s exciting but also moving. It’s a really underserved patient population and a uniformly fatal disease.

Brenda Cooperstone, Pfizer’s chief development officer for rare disease, talking about late-stage clinical trial success of tafamidis, the firm’s experimental treatment for transthyretic cardiomyopathy (April 2)

We developed a way to computationally find matches between rare disease protein structures and functions and existing drug interactions that can help treat patients with some of these orphan diseases.

—Louisiana State University PhD student Misagh Naderi, in a press release announcing her recently published paper on drug repurposing in npj Systems Biology and Applications (March 13)

LUIZA AUGUSTO1. Powerful extensors of...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!